EMVision Trial Passes 230 Patients As Cash Reserves Rise
EMVision’s pivotal brain-scanner trial had recruited more than 230 patients by early October, with most contributing to the primary analysis cohort; the company is also adding acute ischaemic stroke detection for validation within the existing trial, subject to FDA feedback. Cash reserves rose to $18 million at quarter-end from $17 million three months earlier, with further grant funding available. The First Responder study met its initial usability and workflow objectives, while production-equivalent units are targeted for the first half of 2027.
Closing price · 2026-10-26: $1.52 · +4.45%